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A subset of patients with KIT/PDGFRA wild-type gastrointes-
tinal stromal tumors (GISTs) show loss of function of succinate 
dehydrogenase (SDH), resulting in negative immunohisto-
chemical staining for the SDH subunit B (SDHB) protein.1–6 In 
~40 to 50% of cases, the cause of the SDH deficiency is germ-line 
mutation in any of subunits A, B, C, or D, although mutations in 
SDHA are predominant.7 In the remaining cases, the molecular 
cause of tumorigenesis and SDH deficiency is unknown. Other 
molecular events correlated with SDH complex deficiency in 
GIST have recently been described. Epigenomic studies suggest 
a correlation between succinate metabolism and tumor genomic 
methylation.8 Moreover, a microRNA profiling study showed 
that wild-type SDHB-immunonegative tumors present a dis-
tinct pattern compared with KIT/PDGFRA-mutant tumors.9 
The common clinical and pathological features of patients with 
SDH-deficient GIST have been widely described.10 According 
to a small series in which patients were individually described, 
these patients seem to have favorable clinical outcomes even 
after the development of metastases.6,7 To date, however, no 
survival analysis of these patients has been explored. The aim 
of this work was to evaluate a survival analysis of adult patients 
with metastatic KIT/PDGFRA wild-type SDH-deficient GIST 
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Purpose: A subset of patients with KIT/PDGFRA wild-type gastroin-
testinal stromal tumors show loss of function of succinate dehydroge-
nase, mostly due to germ-line mutations of succinate dehydrogenase 
subunits, with a predominance of succinate dehydrogenase subunit 
A. The clinical outcome of these patients seems favorable, as reported 
in small series in which patients were individually described. This 
work evaluates a retrospective survival analysis of a series of patients 
with metastatic KIT/PDGFRA wild-type succinate dehydrogenase–
deficient gastrointestinal stromal tumors.
Methods: Sixty-nine patients with metastatic gastrointestinal stro-
mal tumors were included in the study (11 KIT/PDGFRA wild-type, 
of whom 6 were succinate dehydrogenase deficient, 5 were non–suc-
cinate dehydrogenase deficient, and 58 were KIT/PDGFRA mutant). 
All six succinate dehydrogenase–deficient patients harbored SDHA 
mutations. Kaplan–Meier curves and log-rank tests were used to com-
pare the survival of patients with succinate dehydrogenase subunit 
A–mutant gastrointestinal stromal tumors with that of KIT/PDGFRA 
wild-type patients without succinate dehydrogenase deficiency and 
patients with KIT/PDGFRA-mutant gastrointestinal stromal tumors.
Results: Follow-up ranged from 8.5 to 200.7 months. The differ-
ence between succinate dehydrogenase subunit A–mutant gastroin-
testinal stromal tumors and KIT/PDGFRA-mutant or KIT/PDGFRA 
wild-type non–succinate dehydrogenase deficient gastrointestinal 
stromal tumors was significant considering different analyses (P = 
0.007 and P = 0.033, respectively, from diagnosis of gastrointestinal 
stromal tumor for the whole study population; P = 0.005 and P = 
0.018, respectively, from diagnosis of metastatic disease for the whole 
study population; P = 0.007 for only patients who were metastatic at 
diagnosis).
Conclusion: Patients with metastatic KIT/PDGFRA wild-type 
 succinate dehydrogenase–deficient gastrointestinal stromal tumors 
harboring succinate dehydrogenase subunit A mutations present 
an impressively long survival. These patients should be identified in 
clinical practice to better tailor treatments and follow-up over time.
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as compared with patients with KIT/PDGFRA wild-type non–
SDH-deficient and KIT/PDGFRA-mutant GIST to better define 
the trend of their clinical outcomes in the metastatic setting.
MAteRiALS AnD MetHODS
Patients and tumors
Sixty-nine patients with metastatic GIST who came to our 
clinic from 2004 were retrospectively evaluated and included in 
the study (mean age, 56.2 years (range: 27–79 years); 34 female, 
35 male; 31 stomach, 33 small-intestine, and 5 other tumors).
Nonmetastatic patients and patients with localized GIST 
surgically removed without recurrence were excluded because 
their prognosis is highly affected by other factors, including 
mitotic count and the anatomic site rather than the SDH or 
KIT/PDGFRA genotype. Eleven patients presented with KIT/
PDGFRA wild-type GIST and 58 with KIT/PDGFRA-mutant 
GIST. In all patients with KIT/PDGFRA wild-type GIST, screen-
ing for other tumors, paraganglioma, or pheochromocytoma 
was performed during the follow-up for GIST, and family and 
personal history were assessed. Patients with GIST and a known 
genetic syndrome were excluded because their disease com-
monly has a different natural course than that of sporadic cases.10
For the patients with KIT/PDGFRA wild-type GIST, SDH-
deficient status was assessed by immunohistochemical negativ-
ity for the SDHB protein and by SDH genome sequencing of 
all four subunits. Six of 11 patients had SDH-deficient GIST, 
and 5 patients had non–SDH-deficient GIST. All six patients 
with SDH-deficient GIST had SDHA-mutant GIST, and all 
cases except two have been previously described.2,4,7 None of the 
five patients with KIT/PDGFRA wild-type non–SDH-deficient 
GIST had mutations in any SDH complex subunits.
Forty-nine of 58 patients with KIT/PDGFRA-mutant GIST 
(84%) had a GIST with primary mutations in KIT exon 11, and 
9 patients (16%) had a GIST with a primary mutation in KIT 
exon 9. Exon 18 PDGFRA D842V–mutant GISTs were excluded 
because they are resistant to tyrosine kinase inhibitors, which 
may introduce a bias in a survival study of metastatic GIST.
Statistical analysis
The survival analysis focused on the patients with metastatic 
SDH-deficient GIST (in this study, all patients harbored SDHA 
mutations hereafter referred to as SDHA mutant GIST), as 
compared with patients with metastatic KIT/PDGFRA wild-
type GIST without SDH deficiency and patients with meta-
static KIT/PDGFRA-mutant GIST. Kaplan–Meier curves 
using log-rank tests were developed for the overall survival 
(OS) of all three groups of patients. The survival analyses 
examined (i) the time from diagnosis of GIST to the death of 
the patient or the last follow-up for the whole study popula-
tion, (ii) the time from diagnosis of metastatic disease (at first 
diagnosis or at recurrence) to the death of the patient or the 
last follow-up for the whole study population, and (iii) for 
cases with metastases at diagnosis, the time from diagnosis of 
GIST to the death of the patient or the last follow-up.
ReSULtS
The characteristics and clinical outcomes of patients with 
KIT/PDGFRA wild-type GIST (both SDHA-mutant GIST and 
non–SDH-deficient GIST) are listed in Table 1 (overall mean 
age: 39.7 years (range: 19–65 years); mean age of patients 
with SDHA-mutant GIST: 27 years (range: 19–39 years); and 
mean age of patients with non–SDH-deficient GIST: 55 years 
table 1 Patient/tumor characteristics and outcome data of KIT/PDGFRA wild-type succinate dehydrogenase (SDH)–




























6 23 79, ongoing − Alive (110)




58, ongoing − − − Alive (74)




12 20 82, ongoing − Alive (121)
GIST_150 M 19 Stomach Liver SDHA 
mutated
4 29, ongoing − − Alive (191)
GIST_151 F 21 Stomach Liver SDHA 
mutated
19, ongoing − − − Alive (200)




− − − − Alive (22)
GIST_219 M 44 Stomach Liver, lung SDH WT 6 4 − 2b DOD (68)
GIST_279 F 41 Colon Peritoneum SDH WT 4 3 − 12c, ongoing Alive (35)
GIST_275 F 65 Ileum Peritoneum SDH WT 16 47, ongoing − − DOD (92)
GIST_207 M 62 Ileum Peritoneum SDH WT 36 3 − − DOD (36)
GIST_127 F 63 Ileum Liver, lung SDH WT 4 10, ongoing − − Alive (128)
DOD, dead of disease; TKI, tyrosine kinase inhibitor; WT, wild type.
aPatient reported in ref. 4. bSorafenib. cRegorafenib.
 Volume 17  |  Number 5  |  May 2015  |  GenetiCS in MeDiCine
393
Outcome of SDH-deficient GISTs with SDHA mutations  |  PANTALEO et al Brief report
(range: 41–65 years)). All patients with SDHA-mutant GIST 
except one presented with metastatic disease at the time of 
diagnosis.
Therapeutic management included the following: Two 
patients (GIST_07 and GIST_145) received three lines of 
therapy (imatinib, sunitinib, and nilotinib (now ongoing)), 
and both underwent primary debulking surgery during 
sunitinib treatment; three patients underwent surgery of 
primary tumors and metastases at the time of diagnosis and, 
of them, one patient (GIST_10) then received only imatinib 
(now  ongoing); one patient (GIST_150) received imatinib 
and then sunitinib (now ongoing); and one patient (ID_9) 
did not receive any tyrosine kinase inhibitor therapy. Only 
one patient with SDHA-mutant GIST (GIST_151) pre-
sented with localized disease at diagnosis, underwent radi-
cal surgery of the primary tumor, and at recurrence received 
imatinib (now ongoing). All patients with KIT/PDGFRA 
wild-type GIST without SDH deficiency presented with 
localized disease at the time of diagnosis and underwent 
surgery of primary tumors. At recurrence, the therapeutic 
management of these patients included only tyrosine kinase 
inhibitors, and only one patient (GIST_127) underwent sur-
gery for a solitary hepatic lesion at first recurrence.
Twenty-seven of 58 patients with KIT/PDGFRA-mutant 
GIST (46%) had a localized GIST at diagnosis and then pre-
sented a recurrence, whereas 31 of 58 (54%) presented with 
metastatic disease at diagnosis. The treatment of these patients 
was commonly according to standard guidelines. All of them 
received at least first-line therapy with imatinib, 32 patients 
(55%) received second-line therapy with sunitinib, and 13 
patients (22%) received a third-line therapy (nilotinib, rego-
rafenib, or sorafenib).
Figure 1 Overall survival curves of patients with metastatic succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GiSt) 
(in this study all patients harbored SDH subunit A (SDHA) mutations) as compared with patients with metastatic KIT/PDGFRA wild-type GiSt 
without SDH deficiency and patients with KIT/PDGFRA-mutant GiSt. (a) Time from diagnosis of GIST to the death of the patient or the last follow-up for 
the whole study population. (b) Time from diagnosis of metastatic disease (at first diagnosis or at recurrence) to the death of the patient or the last follow-up 
for the whole study population. (c) Time from diagnosis of GIST to the death of the patient or the last follow-up only for cases with metastases at diagnosis.
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Follow-up data were available for all patients (OS ranged 
between 8.5 and 200.7 months). During this period no deaths 
were observed in the group with SDHA mutations, 3 of 5 deaths 
occurred in the group with KIT/PDGFRA wild-type non–
SDH-deficient GIST, and 28 of 58 deaths occurred in the group 
with KIT/PDGFRA-mutant GIST. The OS curves from diagno-
sis of GIST are reported in Figure 1a; the difference between 
the group with SDHA-mutant GIST and the groups with KIT/
PDGFRA-mutant or KIT/PDGFRA wild-type non–SDH-defi-
cient GIST was significant (P = 0.007 and 0.033, respectively, 
log-rank test). The OS curves considered from the diagnosis 
of metastatic disease are reported in Figure 1b; the difference 
between the group with SDHA-mutant GIST and the groups 
with KIT/PDGFRA-mutant GIST or KIT/PDGFRA wild-type 
non–SDH-deficient GIST was significant (P = 0.005 and 0.018, 
respectively, log-rank test). The OS curves for only the patients 
who had metastatic disease at diagnosis, thus excluding the 
KIT/PDGFRA wild-type non–SDH-deficient group—in which 
all patients had localized disease at diagnosis—are reported 
in Figure 1c; the difference between the group with SDHA-
mutant GIST and the group with KIT/PDGFRA-mutant GIST 
was significant (P = 0.007, log-rank test).
DiSCUSSiOn
According to a small series in which patients were individu-
ally described, patients with SDH-deficient GIST seem to have 
a favorable clinical outcome. Because the aim of this study 
was to describe the clinical course of patients with advanced 
SDH-deficient GIST, we evaluated OS in the metastatic setting. 
We did not analyze progression-free survival or the response 
rate for the following reasons: (i) the aim of this study was 
not to correlate sensitivity to single tyrosine kinase inhibi-
tors with SDH status, which would require a large number of 
patients, even if some published data on sunitinib activity are 
reported for this subset of patients11,12; (ii) most of the patients 
with SDH-deficient GIST received different lines of therapies 
(standard and/or experimental), and the sample size for each 
treatment was too small for any meaningful progression-free 
survival analysis or response rate evaluation; and (iii) two of 
our patients experienced impressive long-term disease stabi-
lization for years during third-line treatment with nilotinib, 
which we suppose likely represents the natural history of the 
disease rather than an effect of the therapy administered.13
The survival analysis showed that SDHA mutations were 
associated with a better clinical outcome as compared with 
KIT/PDGFRA mutations and KIT/PDGFRA wild-type without 
SDH deficiency. The difference in survival between the group 
with SDHA mutations and the group with KIT/PDGFRA muta-
tions was significant in all survival analyses (from diagnosis 
of primary tumors and from diagnosis of metastatic disease). 
These findings are extremely interesting if we consider that 
these patients had metastatic disease at diagnosis and they did 
not have a theoretical chance of cure due to their resistance to 
imatinib, which is the most efficacious targeted treatment in 
patients with GIST.
Also, the difference in survival between the group with SDHA 
mutations and the group with KIT/PDGFRA wild-type without 
SDH deficiency was significant. Moreover, we emphasize that 
the difference in OS values and clinical outcomes between the 
two groups should be considered substantial. In the follow-up 
period, all patients with SDHA mutations are still alive and 
have an extremely long OS, ranging from 74 to 200 months 
(~6 to 16.5 years), except for patient ID_9, in whom GIST was 
diagnosed only 24 months ago (Table 1). OS of patients with-
out SDH deficiency ranged from 35 to 128 months (Table 1). 
Among these patients, however, survival of patients with longer 
follow-up was influenced by additional favorable clinical fea-
tures, such as a long disease-free period between the removal 
of primary tumors and recurrence, and the use of surgery for a 
single hepatic lesion at first recurrence in the patient with 128 
months of follow-up (GIST_127). Unfortunately, our survival 
findings are limited to KIT/PGDFRA wild-type SDH-deficient 
GIST harboring SDHA mutations and do not extend to the 
whole SDH-deficient GIST family. Large numbers of patients 
are needed to show any survival differences between the several 
SDH-deficient groups, such as those with mutations in other 
SDH subunits or those in which the cause of SDH deficiency 
does not depend on SDH gene mutations.
The indolent course of disease for metastatic patients with 
SDHA mutations suggests the importance of recognizing these 
patients in clinical practice. First, all patients carried a germ-
line first-hit mutation in SDHA that required a second-hit 
somatic mutation to develop the tumor. So, given that muta-
tions of the SDH genes are germ-line in patients without a per-
sonal or family history of paraganglioma or other tumors, these 
patients may be carriers of an attenuated form of Carney triad 
and Carney–Stratakis syndrome or a novel, as yet unknown 
syndrome. Therefore, considering the long survival in patients 
with metastatic disease, it is reasonable that all patients with 
KIT/PDGFRA wild-type SDHA mutant GIST should be geneti-
cally tested and strictly monitored over time for the develop-
ment of other tumors.
Second, these patients with metastatic disease could benefit 
from alternative therapeutic approaches that do not adhere at 
all to standard guidelines, for example, primary surgical deb-
ulking or any interval surgery, for which, as is well known, 
the benefit is higher in patients with stable or responding dis-
ease as compared with patients with focal progressing disease. 
However, the indolent nature of the tumors in patients with 
SDHA mutations may make them suitable for such strategies 
also if they develop a mild progression.14,15
Third, the loss of SDHA and, in general, the SDH complex 
may induce a pseudo-hypoxic status, leading to the activation 
of several nuclear genes involved in angiogenesis and prolifera-
tion through similar molecular pathways, as has been observed 
in renal cell cancers that display loss of von Hippel–Lindau 
tumor suppressor function.16 Although the aim of the cur-
rent study was not the evaluation of progression-free survival 
or the response rate to single treatments, for which larger 
series are necessary, all three patients with SDHA mutations 
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with unresectable metastatic disease (GIST_07, GIST_10, and 
GIST_150) (Table 1) demonstrated resistance to imatinib and 
had prolonged disease control on sunitinib. Therefore, SDHA-
mutant GIST could be amenable to anti-angiogenetic inhibitors 
for as long as possible and probably also in patients with disease 
progression and toxicity that may require optimizations of the 
schedule or dosage.
Finally, a correlation between the overexpression of the insu-
lin-like growth factor receptor 1 protein and the status of SDH 
complex deficiency has been reported.17,18 Despite the small 
number of patients with this molecular background reported, 
the data are mature enough to examine whether insulin-like 
growth factor receptor 1 could be considered a target for tri-
als with insulin-like growth factor receptor 1 inhibitors in these 
selected patients.
In conclusion, our findings provide further evidence that 
patients with KIT/PDGFRA wild-type SDH-deficient GIST 
harboring SDHA mutations experience good survival outcomes 
and confirm the necessity of identifying these patients in prac-
tice using a simple immunohistochemistry test for SDHB and 
genetic testing for all patients who are SDHB negative because 
their clinical management in terms of treatments and follow-up 
may benefit from a more patient-tailored approach.
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